NCT00087529View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

439

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

October 31, 2007

Conditions
Multiple Sclerosis
Interventions
DRUG

placebo

Intravenous repeating dose

DRUG

rituximab

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY